CD274 and non-small cell lung carcinoma: Through the analysis of the final 8 high-quality RCTs, enrolling more than 4000 patients with advanced NSCLC, we revealed that PD-L1 inhibitors, when used alone as second-line or later-line treatment, can effectively improve the OS and PFS compared with chemotherapy.